CJC 1295 Research Protocol Reference
A compilation of published research protocol parameters. For laboratory reference only — not a protocol recommendation.
⚠ FOR RESEARCH REFERENCE ONLY — NOT A PROTOCOL RECOMMENDATION. This page summarizes published research parameters and does not constitute guidance for human use. No validated human protocols exist for CJC 1295. All data derives from preclinical studies. See our full disclaimer.
Protocol Overview
FOR RESEARCH REFERENCE ONLY - NOT FOR HUMAN USE
CJC-1295 is a synthetic growth hormone releasing hormone (GHRH) analogue that researchers have investigated for its potential effects on growth hormone secretion. Studies suggest this compound exists in two primary forms: CJC-1295 with Drug Affinity Complex (DAC) modification, which researchers report has an extended half-life of 6-8 days, and CJC-1295 without DAC, with studies indicating a much shorter 30-minute half-life (PMID: 16352683). Research protocols have explored subcutaneous and intramuscular administration routes. This information is for academic research purposes only and should never be used to guide human administration.
Administration & Routes
RESEARCH REFERENCE ONLY - NEVER ADMINISTER TO HUMANS
Published research has explored subcutaneous and intramuscular injection routes for CJC-1295. Studies suggest the subcutaneous route may be preferred due to potentially improved bioavailability and reduced injection site reactions. Researchers have noted that proper sterile technique and injection site rotation appear important in laboratory studies. All administration details are for research reference only and must never be applied to human use.
Dosing Schedule Reference
FOR RESEARCH DOCUMENTATION ONLY
Human studies have explored dosing ranges of 1-2 mg per week for CJC-1295 with DAC modification, administered subcutaneously (PMID: 16352683). Research suggests the extended half-life of the DAC version may allow for less frequent dosing compared to the non-DAC variant. Studies indicate timing may be less critical with the DAC version due to its prolonged activity. These are research observations only and must never guide human dosing protocols.
Cycling & Duration
RESEARCH REFERENCE ONLY - NOT FOR HUMAN APPLICATION
Limited research data exists on optimal cycling protocols for CJC-1295. Some studies suggest researchers have explored continuous administration protocols, while others have investigated intermittent dosing schedules. The extended half-life of CJC-1295 DAC may influence cycling considerations in research settings. All cycling information is for academic reference only and should never inform human use protocols.
Monitoring Parameters
FOR RESEARCH DOCUMENTATION ONLY
Research studies have monitored various parameters including growth hormone levels, IGF-1 concentrations, and potential side effects. Studies suggest monitoring for injection site reactions, water retention, and flushing responses. Some research has explored cardiovascular and metabolic parameter tracking. This monitoring information is for research reference only and must never be used to guide human health monitoring.
Combinations & Stacks
RESEARCH REFERENCE ONLY - NEVER FOR HUMAN USE
Some research has explored CJC-1295 in combination with other growth hormone-related compounds in laboratory settings. Studies have investigated potential synergistic effects with other peptides in the growth hormone pathway. All combination research is for academic reference only and must never inform human protocols.